GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

Mingming Zhang; Guoqing Wei; Linghui Zhou; Jincai Zhou; Siye Chen; Wei Zhang; Dongrui Wang; Xueping Luo; Jiazhen Cui; Simao Huang; Shan Fu; Xinkai Zhou; Yu Tang; Xiaomin Ding; Jiao Kuang; Xiaowen He; Yongxian Hu; He Huang

doi:10.1016/s2352-3026(22)00372-6

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

Mingming Zhang(Zhejiang Chinese Medical University), Guoqing Wei(Zhejiang Chinese Medical University), Linghui Zhou(Zhejiang Chinese Medical University), Jincai Zhou(Regend Therapeutics (China)), Siye Chen(Regend Therapeutics (China)), Wei Zhang(Regend Therapeutics (China)), Dongrui Wang(Zhejiang Chinese Medical University), Xueping Luo(Zhejiang Chinese Medical University), Jiazhen Cui(Zhejiang Chinese Medical University), Simao Huang(Zhejiang Chinese Medical University), Shan Fu(Zhejiang Chinese Medical University), Xinkai Zhou(Zhejiang Chinese Medical University), Yu Tang(Regend Therapeutics (China)), Xiaomin Ding(Regend Therapeutics (China)), Jiao Kuang(Regend Therapeutics (China)), Xiaowen He(Regend Therapeutics (China)), Yongxian Hu(Zhejiang Chinese Medical University), He Huang(Zhejiang Chinese Medical University)

The Lancet Haematology

January 30, 2023

10.1016/s2352-3026(22)00372-6

Cited by 157

Abstract

Related Papers

No related papers found

Powered by citation graph analysis